Bank of America analyst Steve Byrne raised the price objective on Aegerion Pharmaceuticals AEGR from $58 to $100 and maintained a Buy rating. Byrne noted a strong global outlook and less risk to the drug PCSK9 as reasons for the increase.
In the report, Bank of America noted, "We raised our DCF-derived PO for AEGR from $58 to $100 based on several positive updates. Management stated that the US launch for Juxtapid (to treat high cholesterol in patients with a genetic condition called HoFH) has experienced better than expected trends in scripts written, payor coverage, and discontinuationrates. In addition, the CHMP delivered a unanimous opinion to approve the drug (called Lojuxta ex-US)."
The analysts now forecast a loss of $2.18 per share for 2013, better than the consensus loss of $2.24 per share, and expects EPS of $3.16 for 2014 vs. $0.55 consensus. The price target is also now the highest forecast on Wall St.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
